A. Gottlieb, P. Gisondi, J. Eells, L. Peterson, and A. Kavanaugh, “Durability of Response in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study”, J of Skin, vol. 4, no. 1, p. S2, Jan. 2020.